Sanovas, Inc. is a biotechnology and health care startup founded in 2009, headquartered in the United States. The company is dedicated to developing cutting-edge, minimally invasive surgical tools and technologies with a focus on enabling visualization, diagnosis, measurement, and treatment of obstructed passageways in currently inaccessible areas of the body. This approach aims to provide surgeons with faster, less invasive, lower risk, and more cost-effective interventional treatments.
Sanovas is initially targeting the pulmonary market, including the treatment of lung cancer, COPD, asthma, and cystic fibrosis. With a futuristic vision, they aim to address the treatment of diseases and disorders of the six major organ systems of the tubular anatomy in the near future.
At the core of Sanovas' scientific advancements is the miniaturization of tools for minimally invasive surgery. Their revolutionary products extend access beyond current limits, enabling therapeutic intervention in small, one-millimeter diameter regions of the anatomy that were previously inaccessible.
Currently, there is no information available regarding the last investment or the investors involved with Sanovas, Inc.
There is no investment information
No recent news or press coverage available for Sanovas, Inc..
We care about your data, and we'd love to use cookies make your experience better.
